Oncology Drugs

Quetzal Therapeutics’ oral capsule for a rare leukemia could replace grueling IVs. The FDA's Fast Track status signals a major shift for patients and investors.

With a Super Bowl ad, NFL icons like Rob Gronkowski and Novartis are demystifying prostate cancer screening to save lives. Relax, it's a blood test.

The new SecureFlex™ device aims to improve tissue sampling for diseases like pancreatic cancer, enabling more precise diagnoses and personalized treatments.

A single-injection radiotherapy for canine arthritis is proven safe and effective in a new study, changing how vets and owners manage chronic joint pain.

Stoke Therapeutics' major new lease in Waltham signals a pivotal shift to commercialization and defies a cooling life sciences real estate market.

New data reveals Orasis Pharma's Qlosi eye drops offer a 'pupil selective' approach to presbyopia, promising fewer side effects than rival treatments.

New research provides the strongest human evidence that sleep actively clears toxic proteins linked to Alzheimer's, opening a new frontier for prevention.

A new study reveals albumin, the most abundant protein in blood, is a powerful weapon against mucormycosis, offering new hope for treating this fatal infection.

New study shows oral weight loss drug QSYMIA, paired with digital tech, delivers major results, offering a cheaper alternative to pricey injectables.

With promising results in tough-to-treat colorectal cancer, a strong cash runway, and key alliances, Adagene is poised for a pivotal year.

Ontario's new FAST program provides accelerated funding for two key cancer drugs, cutting patient wait times and setting a new standard for access in Canada.

New 24-month data suggests a novel drug could improve kidney function and reduce side effects for transplant patients, challenging a decades-old standard.

An investigational drug from Veloxis Pharmaceuticals has received a key FDA designation, offering new hope for liver transplant patients facing lifelong toxic therapies.

A new therapy for a rare blood cancer gets a major boost from the FDA, offering hope for thousands of myelofibrosis patients with limited options.

A new partnership aims to accelerate mental health innovation by combining a national research network with deep community-based expertise in CNS trials.

With a new CFO known for billion-dollar deals and a promising gout drug, Crystalys Therapeutics is gearing up for a pivotal run at the global market.

Advicenne's novel therapy for distal Renal Tubular Acidosis is under FDA review, potentially bringing the first approved treatment to thousands in the U.S.

At a major San Francisco summit, Chinese biotechs unveiled breakthrough heart and cancer drugs, signaling a strategic shift from manufacturing to global innovation.

With its lead drug in human trials, ViroMissile hires a seasoned CBO to navigate the competitive oncolytic virus market and secure its future.

Basketball legends and the Prostate Cancer Foundation unite in a new initiative to fight late detection, urging men of color to prioritize life-saving screenings.